Abstract

TPS10094 Background: The SIOPEL 3 trial of Cis monotherapy and surgery in SR-HB showed a 3yr OS of 95% at 5 years. SR-HB is defined as tumor extension limited to PRETEXT I, II or III, no involvemen...

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.